Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bluejay DiagnosticsBJDX -8.10%35 EBIT per Share is $-14.02 as of Mar. 2026. GuruFocus rates BJDX with a GF Score™ of 35/100. Among 685 Medical Devices & Instruments companies, Bluejay Diagnostics ranks better than 97.96% on this metric.
Bluejay Diagnostics's EBIT per Share for the
three
months ended in Mar. 2026 was $-1.97.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-14.02.
During the past 3 years, the average EBIT per Share Growth Rate was 88.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Bluejay Diagnostics's EBIT per Share or its related term are showing as below:
BJDX'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 63.3 Med: 75.75 Max: 88.2
Current: 88.2
During the past 7 years, the highest 3-Year average EBIT per Share Growth Rate of Bluejay Diagnostics was 88.20% per year. The lowest was 63.30% per year. And the median was 75.75% per year.
BJDX's 3-Year EBIT Growth Rate is ranked better than 97.96% of 685
companies
in the Medical Devices & Instruments industry
Industry Median: 9.6
vs BJDX: 88.20
Bluejay Diagnostics (NAS:BJDX) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Bluejay Diagnostics EBIT per Share Related Terms
Bluejay Diagnostics EBIT per Share Historical Data
* Premium members only.
The historical data trend for Bluejay Diagnostics's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-14.02
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bluejay Diagnostics (BJDX) has a EBIT per Share of $-14.02 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Bluejay Diagnostics and its competitors. According to the industry distribution chart, Bluejay Diagnostics ranks #14 out of 685 companies in the Medical Devices & Instruments industry, placing it in the top 2%.
Is Bluejay Diagnostics' EBIT per Share too high?
Bluejay Diagnostics' current EBIT per Share is $-14.02. Based on the distribution chart, Bluejay Diagnostics ranks #14 out of 685 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Bluejay Diagnostics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Bluejay Diagnostics' EBIT per Share compare to ALURD and VTAK?
According to the Medical Devices & Instruments industry distribution chart, Bluejay Diagnostics ranks #14 out of 685 companies for EBIT per Share. This places Bluejay Diagnostics in the top 2% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.60, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Bluejay Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bluejay Diagnostics's current EBIT per Share is $-14.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bluejay Diagnostics stock overvalued right now?
Bluejay Diagnostics (BJDX) has a current EBIT per Share of $-14.02. The current EBIT per Share is $-14.02. Bluejay Diagnostics' overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Bluejay Diagnostics (BJDX), the current EBIT per Share is $-14.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bluejay Diagnostics Inc is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay's first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and quicker triage/treatment decisions.
35GF Score
Get the complete analysis for BJDX
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJDX has been successfully added to your 
